|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,565.00 ARS | -1.88% |
|
-1.57% | -20.76% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Private Market | 5.91B | 11.99B | 32.64B | 78.28B | 101B | |||||
Gross Profit | 3.28B | 6.23B | 18.49B | 44.3B | 65.66B | |||||
Net Income | 290M | 183M | -5.27B | 13.42B | 8.83B | |||||
Public Market - Others | 3.02B | 3.12B | 4.97B | 9.88B | 19.62B | |||||
Gross Profit | 1.06B | 1.33B | 1.77B | 3.89B | 8.91B | |||||
Net Income | 141M | 59.41M | -2.11B | 907M | 881M | |||||
Foreign Trade | 458M | 692M | 1.42B | 3.63B | 6.22B | |||||
Gross Profit | 210M | 351M | 295M | 1.83B | 3.62B | |||||
Net Income | 8.49M | -197M | -583M | 169M | 1.01B | |||||
Public Market - Vaccines | 7.22B | 2.67B | - | - | - | |||||
Gross Profit | 381M | 817M | - | - | - | |||||
Net Income | -8.94M | -39.12M | - | - | - | |||||
Net Income | 160M | 156M | -2.89B | 9.35B | -7.56B | |||||
Net Income | - | - | - | - | -80.43M | |||||
Public Market | - | - | - | - | - | |||||
Gross Profit | - | - | - | - | - | |||||
Net Income | - | - | - | - | - | |||||
Pharmaceutical Products | ||||||||||
Pharmaceuticals | - | - | - | - | - | |||||
Interest Expense | - | - | - | - | - | |||||
Income Tax Expense | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
Gross Profit | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Net Income | - | - | - | - | - |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Argentina | 15.6B | 18.64B | 40.15B | 92.98B | 127B | |||||
Foreign | 662M | 624M | 1.26B | 3.28B | 5.56B | |||||
Unallocated Refund for Exports | - | - | - | - | - | |||||
Unallocated Granted Discounts | - | - | - | - | - | |||||
Unallocated Bonuses and Returns | - | - | - | - | - | |||||
Unallocated Gross Income Tax | - | - | - | - | - | |||||
Unallocated | -401M | -790M | -2.38B | -4.46B | -5.81B |
- Stock Market
- Stocks
- RICH Stock
- Financials Laboratorios Richmond S.A.C.I.F.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
















